Renaissance Capital logo

Calithera Biosciences Priced, Nasdaq: CALA

Early-stage biotech developing a drug platform that inhibits tumor metabolism.

Industry: Health Care

First Day Return: -5.9%

Early-stage biotech developing a drug platform that inhibits tumor metabolism.

Calithera Biosciences (CALA) Performance

Created with Highcharts 10.3.2Chart context menuCALA vs. IPO Index (IPOUSA)20152016201720182019202020212022202320242025-100%0%+ 100%+ 200%+ 300%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index